Catalyst PharmaceuticalCPRX
CPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Employees: 167
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 22
25% more capital invested
Capital invested by funds: $1.52B [Q2] → $1.9B (+$377M) [Q3]
15% more funds holding
Funds holding: 270 [Q2] → 311 (+41) [Q3]
2.72% less ownership
Funds ownership: 83.32% [Q2] → 80.6% (-2.72%) [Q3]
10% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 106
25% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]
61% less call options, than puts
Call options by funds: $610K | Put options by funds: $1.58M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
35%
upside
Avg. target
$34
53%
upside
High target
$36
62%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 107 / 339 met price target | 58%upside $35 | Buy Maintained | 10 Jan 2025 |
B of A Securities Jason Gerberry 53% 1-year accuracy 10 / 19 met price target | 35%upside $30 | Buy Reiterated | 9 Jan 2025 |
Stephens & Co. Sudan Loganathan 30% 1-year accuracy 6 / 20 met price target | 58%upside $35 | Overweight Initiated | 18 Nov 2024 |
Truist Securities Joon Lee 44% 1-year accuracy 18 / 41 met price target | 62%upside $36 | Buy Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 10 articles about CPRX published over the past 30 days
Positive
Seeking Alpha
1 day ago
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver.
Positive
Zacks Investment Research
5 days ago
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Positive
Zacks Investment Research
5 days ago
Here's Why Momentum in Catalyst (CPRX) Should Keep going
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Positive
Zacks Investment Research
5 days ago
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Investors Business Daily
6 days ago
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
6 days ago
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Positive
Zacks Investment Research
1 week ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
3 weeks ago
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
GlobeNewsWire
4 weeks ago
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA.
Charts implemented using Lightweight Charts™